[The probability of the carcinogenic risk of using nitrosomethylurea for treating cancer patients].
The results of nitrosomethylurea (NMU) chemotherapy in 12 patients suffering Hodgkin's disease were evaluated. Significant effect was seen in 73.3% with 54.5% in complete remission. Out of 37 survivors for more than 5 years, 26 have survived tumor-free for 7-22 years. Secondary tumor disease (acute lymphoblastic leukemia) was diagnosed in one cases 14 years after diagnosis of Hodgkin's disease stage IIb, which was treated with radiation and standard chemotherapy, and 10 years after combination chemotherapy using NMU as a component for relapse. There is no evidence suggesting any risk of secondary tumor among NMU-treated cancer patients.
Korman
D B
DB
N. M. Emanuel Institute of Biological Physics, Moscow.
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002273:Carcinogens / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008770:Methylnitrosourea / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced; D011336:Probability; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D002273:Carcinogens; D008770:Methylnitrosourea